Day: March 16, 2022

Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results

Written by Customer Service on March 16, 2022. Posted in Earnings Releases And Operating Results.

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023- -Conference call and webcast to be held today at 4:30 p.m. ET- ROCKVILLE, Md., March 16, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today reported financial results for the year ended December 31, 2021, and provided a corporate update. Recent Developments:VCN acquisition: Synthetic Biologics completed the acquisition of privately held VCN Biosciences, developer of a novel oncolytic adenovirus...

Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results

Written by Customer Service on March 16, 2022. Posted in Earnings Releases And Operating Results.

Fourth Quarter 2021 Revenue of $6.1 million Fourth Quarter 2021 Net Income of $1.0 million and EPS of $0.04DEER PARK, Ill., March 16, 2022 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the fourth quarter ended December 31, 2021. “Our business has never been stronger. The carglumic acid launch is tracking ahead of our initial expectations, the recently implemented co-promotion partnership with Tolmar has accelerated growth of ALKINDI SPRINKLE®, and just this week we launched another new product, Rezipres,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “In addition, we continue to make progress with our four additional products that have been submitted to the FDA,...

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 16, 2022. Posted in Earnings Releases And Operating Results.

SAN DIEGO and REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update. “2021 was a momentous year for eFFECTOR, as we advanced both our clinical stage assets, tomivosertib and zotatifin, into Phase 2 trials and raised additional capital with our debut as a public company,” said Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR. “In early 2022, we announced an optimized design for KICKSTART, our randomized Phase 2b trial of tomivosertib combined with pembrolizumab in patients with PD-L1 positive non-small cell lung cancer, a population...

North Dallas Bank & Trust Co. Declares Regular Dividend

Written by Customer Service on March 16, 2022. Posted in Dividend Reports And Estimates.

DALLAS, March 16, 2022 (GLOBE NEWSWIRE) — On March 15, 2022, the Board of Directors of North Dallas Bank & Trust Co. (OTC: NODB), declared a regular dividend of $0.33 per share, payable to shareholders of record as of April 1, 2022, with said dividend payable on April 8, 2022. The current dividend represents an increase over regular dividends paid in the prior year and reflects the Bank’s (“NDBT”) preference going forward to reward shareholder’s through payment of regular dividends, as opposed to historic practice of paying both regular and special dividends. The current dividends are based on NDBT’s current financial condition and are not a guarantee that dividends will continue to be paid in the future. Further information about NDBT’s dividend declaration is available from Glenn Henry, Chief Financial Officer. ABOUT NDBTFounded...

Abacus completes final tranche of its non-brokered private placement

Written by Customer Service on March 16, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, March 16, 2022 (GLOBE NEWSWIRE) — Abacus Mining & Exploration Corporation (“Abacus” or the “Company”) (TSXV: AME) is pleased to announce the closing of the second and final tranche of its non-brokered private placement of units (the “Private Placement”), as announced on February 23, 2022, February 28, 2022, March 2, 2022 and March 10, 2022. Pursuant to the final tranche of the Private Placement, the Company raised total gross proceed of $60,000, and issued 1,000,000 units (“Units”) at a price of $0.06 per Unit. Each Unit consists of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (a “Warrant”), with each full Warrant exercisable to purchase one Share at a price of $0.10 per Share until March 16, 2024. All securities issued in connection with the final...

CHAR Technologies Announces Further Increase in Private Placement to $4.89 Million

Written by Customer Service on March 16, 2022. Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES TORONTO, March 16, 2022 (GLOBE NEWSWIRE) — CHAR Technologies Ltd. (“CHAR Technologies” or the “Company”) (TSX Venture Exchange: YES) is pleased to announce its intention, in response to investor demand, to further increase the size of the $3,000,000 non-brokered private placement (the “Offering”) it announced on February 9, 2022, to a final total size of up to $4,894,881. The size of the Offering was first increased from $3,000,000 to $4,605,000, as announced in the Company’s March 8, 2022 news release. The Company now intends a further increase of up to 644,181 units at the offering price of $0.45 per unit for additional gross proceeds of up to $289,881. The total Offering will now amount to up to 10,877,514...

UPDATE: Gb Sciences Issues Shareholder Letter

Written by Customer Service on March 16, 2022. Posted in Public Companies.

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021GB GBLAS VEGAS, March 16, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to shareholders from President, Chief Science Officer, and Director Dr. Andrea Small-Howard and Chairman and CEO John Poss, summarizing key developments from 2021 and providing strategic plans for 2022. Full text of the shareholder letter follows. A MESSAGE FROM BOTH THE PRESIDENT AND THE CHAIRMAN OF GB SCIENCES, INC. To Our Shareholders: 2021 was a transformational year for Gb Sciences. In December 2021, we sold our last cannabis production facility to become a pure-play biopharmaceutical...

Kadant Releases its 2021 Corporate Sustainability Report

Written by Customer Service on March 16, 2022. Posted in Public Companies.

WESTFORD, Mass., March 16, 2022 (GLOBE NEWSWIRE) — Kadant Inc. (NYSE: KAI) released its 2021 corporate sustainability report, which can be viewed at www.kadant.com/about-us/sustainability. The report highlights the Company’s continued commitment and progress on environmental, social, and governance (ESG) initiatives. “I am proud of the results we delivered in 2021 and the progress we made on our corporate sustainability goals,” said Jeffrey L. Powell, president and chief executive officer of Kadant. “Our focus on helping our customers advance their sustainability initiatives by providing technologies and engineered solutions that reduce waste and increase yield with fewer inputs is making a positive difference for all our stakeholders.” The 2021 report is prepared according to Global Reporting Initiative (GRI) and Sustainability...

VALUE LINE, INC. ANNOUNCES INCREASE IN NET INCOME AND RENEWS STOCK REPURCHASE PROGRAM

Written by Customer Service on March 16, 2022. Posted in Public Companies.

For Immediate Release NEWS RELEASE www.valueline.com www.ValueLinePro.com, www.ValueLineLibrary.com Facebook | LinkedIn | Twitter Complimentary Value Line® Reports on Dow 30 Stocks New York, March 16, 2022 (GLOBE NEWSWIRE) — Value Line, Inc., (NASDAQ: VALU) reported results through the third fiscal quarter ended January 31, 2022. Shareholders’ equity reached $79,401,000 at January 31, 2022, an increase of 24.9% over the shareholders’ equity of $63,569,000 at January 31, 2021. Retained earnings at January 31, 2022, were $86,216,000, representing an increase of 27.7% over retained earnings at January 31, 2021. The Company’s current assets at January 31, 2022, were $61,114,000, a 34.5% increase over current assets at January 31, 2021. During the nine months (May 2021 through January 2022), the Company’s net income of $20,015,000,...

Marel: Results of the AGM 16 March 2022

Written by Customer Service on March 16, 2022. Posted in Public Companies.

Marel’s virtual Annual General Meeting was held on 16 March 2022 at 16:00 GMT. All proposals of the Board of Directors to the meeting were approved. The proposals and other relevant materials are available on the AGM website: marel.com/agm. Further information on votes cast at the meeting is attached. Chairman Arnar Thor Masson, addressed the meeting on behalf of the Board of Directors. CEO Arni Oddur Thordarson reported the Company’s 2021 consolidated financial statements and gave an overview of the Company’s business activities. From Chairman Arnar Thor Masson’s statement: “In 2021, Marel further intensified its progress towards its mid-term and long-term targets. We launched new breakthrough innovations, invested in our global reach and manufacturing facilities, and completed bolt-on acquisitions. By providing the best-in-class digital...

Day: March 16, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice